Adaptimmune Therapeutics Plc ADR (ADAP) concluded trading on Thursday at a closing price of $0.28, with 13.94 million shares of worth about $3.9 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -73.33% during that period and on March 20, 2025 the price saw a loss of about -37.65%. Currently the company’s common shares owned by public are about 255.70M shares, out of which, 226.47M shares are available for trading.
Stock saw a price change of -37.51% in past 5 days and over the past one month there was a price change of -51.60%. Year-to-date (YTD), ADAP shares are showing a performance of -48.02% which decreased to -80.95% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.44 but also hit the highest price of $1.65 during that period. The average intraday trading volume for Adaptimmune Therapeutics Plc ADR shares is 1.36 million. The stock is currently trading -42.46% below its 20-day simple moving average (SMA20), while that difference is down -49.05% for SMA50 and it goes to -66.49% lower than SMA200.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) currently have 255.70M outstanding shares and institutions hold larger chunk of about 37.31% of that.
The stock has a current market capitalization of $71.65M and its 3Y-monthly beta is at 2.61. It has posted earnings per share of -$0.21 in the same period. It has Quick Ratio of 3.82 while making debt-to-equity ratio of 0.93. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADAP, volatility over the week remained 17.88% while standing at 11.35% over the month.
Stock’s fiscal year EPS is expected to rise by 64.33% while it is estimated to decrease by -201.25% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on July 30, 2024 offering a Buy rating for the stock and assigned a target price of $4 to it. Coverage by Scotiabank stated Adaptimmune Therapeutics Plc ADR (ADAP) stock as a Sector outperform in their note to investors on May 30, 2024, suggesting a price target of $3.15 for the stock. On March 24, 2023, Bryan Garnier Initiated their recommendations, while on January 03, 2023, Guggenheim Upgrade their ratings for the stock with a price target of $5. Stock get a Buy rating from Mizuho on November 09, 2022.
